IL2 and melanoma: Similar to systemic IL-2, only a subset of patients will experience a durable benefit from this approach, but we recently reported an encouraging median OS of 7.8 months and a 5-year OS of 13% for IT IL-2 treatment in a cohort of highly selected melanoma LMD patients, and provided initial evidence that IT immunotherapy can potentially result in long-term survival in a subset of patients with LMD16.